Latent tb full details for md exam answer 15 marks
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information from multiple authoritative textbooks. Let me compose the full 15-mark MD exam answer.
Latent Tuberculosis Infection (LTBI) — Complete MD Exam Answer (15 Marks)
1. Definition
Latent tuberculosis infection (LTBI) is a state in which Mycobacterium tuberculosis persists within the host in a dormant, non-replicating form, controlled by the immune system, but not eliminated. The individual has no symptoms, is not infectious, and has negative cultures — yet carries viable bacilli capable of reactivation.
"The distinction between latent tuberculosis infection and active disease is extremely important clinically." — Goldman-Cecil Medicine
Approximately 1.7 billion people (22% of the world's population) are estimated to have LTBI; 5–10% of latently infected individuals will develop active disease if untreated.
2. Pathogenesis and Mechanism of Latency
Primary infection:
- M. tuberculosis is inhaled in droplet nuclei (1–5 μm), reaching the alveoli.
- Alveolar macrophages engulf the bacilli, but the organism subverts the innate immune response — inhibiting phagosome-lysosome fusion, resisting acidification, and evading ROS killing.
- A Th1-mediated immune response develops 3–4 weeks post-exposure, containing (but not always eliminating) infection.
Transition to latency:
- When faced with oxygen and nutrient deprivation (e.g., within granulomas), M. tuberculosis deploys nitrogen metabolism regulators and hypoxia-response regulators (DosR/DevR regulon) to enter a prolonged dormant state.
- Latent bacilli are primarily in healed granulomas (Ghon focus) in the lung, but are widely distributed throughout the body — in lymph nodes, bone marrow, kidneys, and elsewhere, with or without granulomatous inflammation.
- Primary lesions heal by fibrosis; the Ghon complex → calcified Ranke complex (calcified parenchymal lesion + calcified hilar nodes) on CXR.
Why bacilli survive:
- The waxy mycobacterial cell wall (mycolic acid-rich) is highly resistant.
- Some bacilli downregulate metabolic activity (non-replicating persistence).
- Resuscitation-promoting factor (Rpf) proteins facilitate later reactivation.
— Sherris & Ryan's Medical Microbiology, 8th Ed.
3. Risk Factors for LTBI and Progression to Active Disease
| Category | Risk Factor | TST Cut-off |
|---|---|---|
| Increased risk of infection | Household contact of active TB case | ≥5 mm |
| Born/lived in high-prevalence countries | ≥10 mm | |
| Residents/employees of prisons, homeless shelters, nursing homes, hospitals | ≥10 mm | |
| Children <5 yrs exposed to high-risk adults | ≥10 mm | |
| Increased risk of progression | HIV infection | ≥5 mm |
| Solid organ transplant, TNF-α inhibitors, steroids (>15 mg/day >1 month) | ≥5 mm | |
| Fibrotic lesion on CXR consistent with old TB | ≥5 mm | |
| DM (especially insulin-dependent/poorly controlled) | ≥10 mm | |
| Silicosis, end-stage renal disease, underweight (BMI ≤20) | ≥10 mm | |
| Lymphoma, leukemia, head/neck/lung malignancy | ≥10 mm | |
| Cigarette smoking | ≥10 mm | |
| General population | No risk factors | ≥15 mm |
Lifetime risk of reactivation: ~10% overall; ~3–4% in the first year after seroconversion; 30–50% in HIV co-infection; much higher with immunosuppressive therapy.
— Goldman-Cecil Medicine, Table 299-1
4. Diagnosis
Principle
LTBI is a clinical diagnosis — there is no gold-standard direct diagnostic test. Active TB must first be excluded. Diagnosis rests on:
- Demonstrating immunologic response to M. tuberculosis antigens
- Excluding active disease (symptoms, CXR, sputum)
A. Tuberculin Skin Test (TST / Mantoux Test)
- Antigen: 5 TU of purified protein derivative (PPD) intradermally (Mantoux method)
- Reading: Induration (not erythema) measured in mm at 48–72 hours
- Interpretation: (see Table above for cut-offs)
- Limitations:
- False positives: Prior BCG vaccination, non-tuberculous mycobacteria (NTM) — cross-reactive antigens (PPD includes ESAT-6 region cross-reactive with M. bovis BCG)
- False negatives: Immunosuppression (HIV, malnutrition, sarcoidosis), very recent infection (<8 weeks), overwhelming active TB ("anergy"), improper technique/storage
- Booster effect: Two-step testing needed in older adults
B. Interferon-Gamma Release Assays (IGRAs)
- Types available: QuantiFERON-TB Gold Plus (QFT-Plus), T-SPOT.TB
- Principle: Whole blood stimulated with TB-specific antigens (ESAT-6 and CFP-10) — these are absent from BCG and most NTM, giving greater specificity than TST
- Result: Measured IFN-γ release (ELISA) or IFN-γ-producing T-cells (ELISPOT)
- Advantages: Single visit; not affected by BCG vaccination; no reader subjectivity
- Limitations: Expensive; requires laboratory processing within 8–30 hours; uninterpretable results more common in children <5 years (up to 40%)
When to Use TST vs IGRA:
| Situation | Preferred Test |
|---|---|
| Children <5 years | TST preferred (IGRA acceptable) |
| Prior BCG vaccination | IGRA preferred |
| Poor follow-up populations (homeless, drug users) | IGRA preferred |
| Both tests negative but high suspicion | Dual testing (IGRA + TST) |
| BCG-vaccinated with positive TST needing confirmation | Dual testing |
C. Radiological findings (Incidental, not diagnostic)
- Ghon lesion: Calcified peripheral parenchymal nodule (mid-lung field)
- Ranke complex: Ghon lesion + calcified hilar/paratracheal nodes
- These are non-specific (also seen in healed histoplasmosis)
- CXR is used primarily to exclude active disease before treating LTBI
Spectrum of TB Infection (Figure 299-3, Goldman-Cecil):
| Parameter | LTBI (Latent) | Active TB |
|---|---|---|
| TST/IGRA | Positive | Usually positive |
| Sputum culture | Negative | Positive |
| Smear | Negative | Positive/negative |
| Infectious | No | Yes |
| Symptoms | None | Mild to severe |
| Treatment | Preventive therapy | Multidrug therapy |
5. Treatment of LTBI (Preventive Therapy)
Goal: Reduce risk of progression to active TB by 75–90%
Prerequisites before initiating treatment:
- Confirm LTBI (positive TST or IGRA)
- Exclude active TB (clinical history, physical examination, CXR, sputum if indicated)
- Assess for drug interactions and hepatotoxicity risk
- Supplement with Pyridoxine (Vitamin B6) in all INH-containing regimens (25–50 mg/day) — prevents INH-induced peripheral neuropathy
Recommended Regimens (CDC/WHO Guidelines):
| Regimen | Duration | Frequency | Dose | Notes |
|---|---|---|---|---|
| 1HP: INH + Rifapentine | 3 months | Once weekly | INH 900 mg + RPT 900 mg | Preferred — shortest, best adherence |
| 4R: Rifampin alone | 4 months | Daily | 10 mg/kg (max 600 mg) | Preferred if INH-resistant contact |
| 3HR: INH + Rifampin | 3 months | Daily | INH 300 mg + RIF 600 mg | Alternative short course |
| 9H: INH alone | 9 months | Daily | 5 mg/kg (max 300 mg) | Preferred in pregnancy; longest but most studied |
| 6H: INH alone | 6 months | Daily | 5 mg/kg (max 300 mg) | Alternative; not for children |
Key point for exams: The 3HP (1HP) regimen (INH + Rifapentine once weekly × 12 doses) is now the preferred regimen due to high completion rates. The older 9H (INH × 9 months) was the traditional standard.
— Goldman-Cecil Medicine, Table 299-2; Murray & Nadel's Respiratory Medicine, Table 42.4
Monitoring for toxicity:
| Drug | Key Toxicity | Monitoring |
|---|---|---|
| Isoniazid (INH) | Hepatotoxicity, peripheral neuropathy, drug-induced lupus | LFTs at baseline; repeat if symptomatic; give B6 |
| Rifampin | Hepatotoxicity, drug interactions (CYP450 inducer), orange discoloration of body fluids | LFTs; check drug interactions (OCP, antiretrovirals, warfarin) |
| Rifapentine | Same as rifampin | As above |
Contraindications/Cautions:
- Active hepatitis or end-stage liver disease → avoid INH
- HIV patients on certain antiretrovirals → prefer 4R (avoid rifampin/rifapentine due to interactions)
- Pregnancy → 9H (INH) preferred; avoid rifapentine
6. Special Situations
HIV/LTBI Co-infection
- Risk of reactivation is 30–100× higher in HIV-infected individuals
- All HIV-positive patients with positive TST/IGRA should receive preventive therapy
- IGRA preferred for diagnosis (TST may be falsely negative due to anergy)
- Preferred regimen: 9H or 3HP (with attention to ART drug interactions)
BCG and LTBI Testing
- BCG vaccination causes false-positive TST
- IGRA is preferred in BCG-vaccinated individuals (ESAT-6/CFP-10 antigens absent from BCG)
Immunosuppressive therapy (Biologics, TNF-α inhibitors)
- All patients must be screened for LTBI before starting anti-TNF therapy (e.g., infliximab, adalimumab) or other immunosuppressants
- The National Psoriasis Foundation recommends delaying immunologic therapy until prophylaxis for LTBI has been initiated
Drug-Resistant Contact
- If source case has INH-resistant TB → use 4R (Rifampin × 4 months)
- If source case has MDR-TB → no proven regimen; expert consultation required
7. Prevention (Public Health)
- Case finding and contact tracing: Testing all household contacts of active TB cases
- Targeted testing: Focus on high-risk groups (see Table above)
- BCG vaccine: Protects children against severe TB (meningitis, miliary TB) but does not reliably prevent LTBI or reactivation in adults
- Environmental measures: Negative pressure isolation rooms, HEPA filtration, N95 masks for healthcare workers, surgical masks for patients
- End TB Strategy (WHO): Includes LTBI treatment as a pillar; COVID-19 pandemic disrupted progress — 1.4 million fewer cases reported in 2020 (likely underreporting), with projected 0.5 million excess TB deaths
8. Key Points Summary (Exam Pearls)
| Point | Detail |
|---|---|
| Prevalence | 1.7 billion (22% global population) |
| Risk of activation (untreated) | 5–10% lifetime; 3–4% in first year |
| HIV co-infection | Increases risk 30–100× |
| Diagnostic tests | TST (Mantoux) and IGRAs — both indirect |
| TST cut-off (HIV/close contact) | ≥5 mm |
| IGRA advantage | Not affected by BCG; single visit |
| Preferred short regimen | 3HP — INH + Rifapentine × 12 weekly doses |
| INH prophylaxis (traditional) | 9 months daily (max 300 mg/day) |
| Must exclude before treating | Active TB (CXR + sputum) |
| Efficacy of treatment | Reduces risk by 75–90% |
| Pyridoxine (B6) | Always co-prescribe with INH |
| Pathological hallmark | Healed granuloma → Ghon/Ranke complex |
| Mechanism of latency | Hypoxia → dormancy via DosR regulon |
Sources:
- Goldman-Cecil Medicine International Edition (Chapter 299)
- Murray & Nadel's Textbook of Respiratory Medicine (Chapter 42)
- Sherris & Ryan's Medical Microbiology, 8th Edition (Chapter 27)
- Harrison's Principles of Internal Medicine, 22nd Edition
This is a shared conversation. Sign in to Orris to start your own chat.